Heath RB, Jones R, Frayn KN, Robertson MD Vagal stimulation exaggerates the inhibitory ghrelin response to oral fat in humans. J Endocrinol. 2004 Feb;180(2):273-81.
Heyman S Gastric emptying in children. J Nucl Med. 1998 May;39(5):865-9. Review.
Hou XH, Li Q, Zhu L, Xie X, Chen JD Correlation of gastric liquid emptying with various thresholds of sensation in healthy controls and patients with functional dyspepsia. Dig Dis Sci. 2004 Feb;49(2):188-95.
Hyams JS, Hyman PE Recurrent abdominal pain and the biopsychosocial model of medical practice. J Pediatr. 1998 Oct;133(4):473-8. Review.
Lee KJ, Cha DY, Cheon SJ, Yeo M, Cho SW Plasma ghrelin levels and their relationship with gastric emptying in patients with dysmotility-like functional dyspepsia. Digestion. 2009;80(1):58-63. doi: 10.1159/000215389. Epub 2009 Jun 3.
Lin Z, Eaker EY, Sarosiek I, McCallum RW Gastric myoelectrical activity and gastric emptying in patients with functional dyspepsia. Am J Gastroenterol. 1999 Sep;94(9):2384-9.
Nishizawa T, Suzuki H, Nomoto Y et al Enhanced plasma ghrelin levels in patients with functional dyspepsia. Aliment. Pharmacol. Ther. 2006; 24 (Suppl. 4): 104-10. 02.01.12
Ogiso K, Asakawa A, Amitani H, Inui A Ghrelin: a gut hormonal basis of motility regulation and functional dyspepsia. J Gastroenterol Hepatol. 2011 Apr;26 Suppl 3:67-72. doi: 10.1111/j.1440-1746.2011.06630.x. Review.
Schurman JV, Singh M, Singh V, Neilan N, Friesen CA Symptoms and subtypes in pediatric functional dyspepsia: relation to mucosal inflammation and psychological functioning. J Pediatr Gastroenterol Nutr. 2010 Sep;51(3):298-303. doi: 10.1097/MPG.0b013e3181d1363c.
Suzuki H, Nishizawa T, Hibi T Therapeutic strategies for functional dyspepsia and the introduction of the Rome III classification. J Gastroenterol. 2006 Jun;41(6):513-23. Review.
Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.
Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.
Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.
Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.
Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.